A Phase 1 interventional study of PNU-100480 and PNU-100480 in Tuberculosis, sponsored by Sequella, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-27.
Sponsored by Sequella, Inc. · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.
Among the 129 studies in Tuberculosis with a site in United States, this one is the 76th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2009, is one of 44 in phase 1, and was the 48th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 21+
Columbia University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mexico
Ages 18–99
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 13 · Phase 3 8 · Phase 4 8
First in 1992; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 56 across the 94 interventional studies, 151 across the 32 observational. Of the 117 that completed or were terminated, 35 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 129 have an industry lead sponsor. The 10 most frequent:
Sequella, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Sequella, Inc. has 4 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Tuberculosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07737275Columbia UniversityScreening With Portable X-rays for Rapid Recognition of TB | 2027-05-25 |
Add it to your calendar (.ics) → With an account.
Among the 129 studies in Tuberculosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PNU-100480 (PF-02341272) after a single dose in healthy adult volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
Drug: PNU-100480 · Drug: Placebo
Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
Drug: PNU-100480 · Drug: Placebo
Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
Drug: PNU-100480 · Drug: Placebo
Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
Drug: PNU-100480 · Drug: Placebo
Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
Drug: PNU-100480 · Drug: Placebo
Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
Drug: PNU-100480 · Drug: Placebo
100 mg oral suspension given once
Also known as: Period 2
300 mg oral suspension given once
Also known as: Period 3
placebo to match oral suspension given once
Also known as: Period 1
300 mg oral suspension given once
Also known as: Period 3
35 mg oral suspension given once
Also known as: Period 1
placebo to match oral suspension given once
Also known as: Period 2
100 mg oral suspension given once
Also known as: Period 2
35 mg oral suspension given once
Also known as: Period 1
placebo to match oral suspension given once
Also known as: Period 3
1000 mg oral suspension given once
Also known as: Period 2
1500 mg oral suspension given once
Also known as: Period 3
Fed conditions, 600 mg oral suspension given once
Also known as: Period 4 (Fed)
placebo to match oral suspension given once
Also known as: Period 1
1500 mg oral suspension given once
Also known as: Period 3
600 mg oral suspension given once
Also known as: Period 1
Fed conditions, 600 mg oral suspension given once
Also known as: Period 4 (Fed)
placebo to match oral suspension given once
Also known as: Period 2
1000 mg oral suspension given once
Also known as: Period 2
600 mg oral suspension given once
Also known as: Period 1
Fed conditions, 600 mg oral suspension given once
Also known as: Period 4 (Fed)
placebo to match oral suspension given once
Also known as: Period 3
Evaluation of safety and tolerability of escalating single oral doses of PNU-100480.
Time frame: Daily, Days 1-3 or 4, and 7-14 days after dosing.
Characterize pharmacokinetics of single oral doses PNU-100480.
Time frame: Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.
Characterize the effect of food on the pharmacokinetics of a single oral dose of PNU-100480.
Time frame: Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.
Characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular Mycobacterium tuberculosis in relation to blood concentrations of PNU-100480 (and its metabolites) (some periods only)
Time frame: Predose and timpoints up to 24 hours post dose on Day 1 (only in some periods)
The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PNU-100480
Sequella, Inc.